|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2001-1-3
|
|
pubmed:abstractText |
We evaluated the effectiveness and safety profile of 10 and 20 mg of rabeprazole, a new proton pump inhibitor, once daily versus placebo in preventing endoscopic and symptomatic relapse for up to 1 yr among patients with healed erosive or ulcerative gastroesophageal reflux disease (GERD).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0002-9270
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3081-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11095321-2-Pyridinylmethylsulfinylbenzimidazoles,
pubmed-meshheading:11095321-Anti-Ulcer Agents,
pubmed-meshheading:11095321-Benzimidazoles,
pubmed-meshheading:11095321-Dose-Response Relationship, Drug,
pubmed-meshheading:11095321-Double-Blind Method,
pubmed-meshheading:11095321-Esophagitis, Peptic,
pubmed-meshheading:11095321-Female,
pubmed-meshheading:11095321-Follow-Up Studies,
pubmed-meshheading:11095321-Gastroesophageal Reflux,
pubmed-meshheading:11095321-Humans,
pubmed-meshheading:11095321-Male,
pubmed-meshheading:11095321-Middle Aged,
pubmed-meshheading:11095321-Omeprazole,
pubmed-meshheading:11095321-Proton Pumps,
pubmed-meshheading:11095321-Proton-Translocating ATPases,
pubmed-meshheading:11095321-Recurrence,
pubmed-meshheading:11095321-Safety,
pubmed-meshheading:11095321-Time Factors
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
|
|
pubmed:affiliation |
Central Florida Clinical Studies, Ocoee, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
